Congressional Criticism of Medicare Funding Cuts in Recent Bill
Congressman Vicente Gonzalez criticizes recent Medicare funding cuts in a newly passed bill, highlighting potential impacts on seniors and the insurance industry.
Congressman Vicente Gonzalez criticizes recent Medicare funding cuts in a newly passed bill, highlighting potential impacts on seniors and the insurance industry.
Health insurance premiums in the Affordable Care Act marketplace are projected to increase by 15% in 2025, driven by rising medical costs, new drug expenses, tariffs, and uncertain subsidy extensions.
Explore the implications of enrolling in Medicare Advantage plans and later switching to original Medicare with Medigap, focusing on medical underwriting and enrollment restrictions that impact U.S. beneficiaries.
Texas recently expanded Medigap coverage options for Medicare beneficiaries under 65 with end-stage kidney disease, improving insurance access and affordability. NKF advocacy played a key role in this policy change.
Enhanced ACA subsidies are set to expire, risking significant premium hikes and coverage losses in high-enrollment states like Florida and Texas. Understand the regulatory and market impacts.
Explore how medical debt financing companies support rural hospitals facing financial challenges amid Medicaid and ACA funding cuts, impacting uninsured patients and hospital revenue cycles.
New legislation expanding Individual Coverage Health Reimbursement Arrangements (ICHRAs) aims to increase employer-sponsored health insurance flexibility, reduce costs, and enhance consumer choice in the U.S. market.
House tax and spending bill could cause 11 million Americans to lose health insurance due to deep cuts in Medicaid and ACA subsidies, raising costs and enrollment barriers.
The House reconciliation bill introduces major ACA subsidy cuts and Medicaid funding reductions, threatening health coverage for 14 million Americans while increasing administrative barriers.
Medicare beneficiaries face higher costs as Part D plans shift from fixed co-pays to coinsurance for expensive Tier 3 drugs, raising out-of-pocket expenses significantly.